Latest Headlines

Latest Headlines

Merck extends Ablynx immuno-oncology relationship with heavily backloaded €4B deal

Ablynx has extended its immuno-oncology pact with Merck, boosting its potential earnings from the alliance by €4 billion ($4.4 billion) through the addition of up to 12 new programmes. But Ablynx will have to wait a while for its paydays, with just €13 million of the cash arriving as an upfront payment.

Top 10 pharma companies in social media

Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....

Expect vaccines market to swell to $40B by 2020: Tufts CSDD

Two recently-published market analyses paint a picture of a competitive but growing vaccines field through 2020, with the newest report from Tufts University stating the industry is on track to post $40 billion in annual sales in 5 years.

Merck invests $6M in microbial diagnostics specialist OpGen

The Merck Global Health Innovation Fund invested $6 million in OpGen on the same day the microbial genetics specialist announced it will acquire AdvanDx, a maker of molecular tests for blood cultures.

Biopharma's 10 highest-paid heads of R&D

The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.

EMA to again place HPV vaccines under its safety lens

While the European Medicines Agency said it "does not question that the benefits of HPV vaccines outweigh their risks," on Monday it announced a safety review of the shots that have thus far failed to live up to expectations partly due to safety concerns and a sex-related stigma.

European safety watchdog digs into HPV vaccines again

After years of fighting off safety concerns and a perceived sex-related stigma for their HPV vaccines, Merck and GlaxoSmithKline will face another test with their respective jabs in Europe.

How does the Keytruda-Opdivo marketing battle stack up?

Merck's Keytruda and Bristol-Myers Squibb's Opdivo may be two of the most watched drugs in pharma right now. That's not only because both are breakthrough immunotherapy cancer treatments, but also because both are racing to win additional indications. And when it comes to marketing, each one is playing its advantage.

Merck, Samsung rack up data on Humira biosim, setting stage for approval apps

Industry watchers expect biosimilars for AbbVie's Humira to be the most successful copycat biologics launched in the U.S. and Europe, and that's something Merck and Samsung are trying to get in on.

Merck and Samsung's Humira biosimilar comes through in Phase III

Partners Merck and Samsung Bioepis cleared late-stage trials with their knockoff of Humira, the world's top-selling medicine, setting the stage for global regulatory applications as the reference treatment comes off patent.